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Effect of 6p21 region on lung 
function is modified by smoking: 
a genome‑wide interaction study
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Keum Ji Jung6, Sun Ha Jee6, Woo Jin Kim7, Michael H. Cho8,9, Edwin K. Silverman8,9, 
Taesung Park2,10* & Sungho Won1,2,11*
Smoking is a major risk factor for chronic obstructive pulmonary disease (COPD); however, more 
than 25% of COPD patients are non‑smokers, and gene‑by‑smoking interactions are expected to 
affect COPD onset. We aimed to identify the common genetic variants interacting with pack‑years of 
smoking on  FEV1/FVC ratios in individuals with normal lung function. A genome‑wide interaction study 
(GWIS) on  FEV1/FVC was performed for individuals with  FEV1/FVC ratio ≥ 70 in the Korea Associated 
Resource cohort data, and significant SNPs were validated using data from two other Korean 
cohorts. The GWIS revealed that rs10947231 and rs8192575 met genome‑wide significant levels; For 
H0 : βSNP = βSNP∗pack−years = 0 vs H1 : notH0, the likelihood ratio (LR) test was conducted, and its P 
values, PLR, for rs10947231 and rs8192575 were 2.23 × 10–12 and 1.18 × 10–8, respectively. Interaction 
between rs8192575 and smoking is significantly replicated with two additional data (Pint = 0.0454, 
0.0131). Expression quantitative trait loci, topologically associated domains, and PrediXcan analyses 
revealed that rs8192575 is significantly associated with AGER expression. SNPs on the 6p21 region 
are associated with  FEV1/FVC, and the effect of smoking on  FEV1/FVC differs among the associated 
genotypes.
Chronic obstructive pulmonary disease (COPD) is a common respiratory disease with high worldwide morbid-
ity and  mortality1, characterized by progressive airflow  obstruction2. Although cigarette smoking is the major 
environmental risk factor for COPD, multiple factors can contribute to this disease, including air pollution, infec-
tion, and  asthma1,3. However, sensitivity to smoking differs among individuals, and only a minority of smokers 
develop  COPD4,5, highlighting the potential importance of genetic architecture. Severe α1-antitrypsin (AAT) 
deficiency is the best known genetic risk factor for  COPD6, and genome-wide association studies (GWAS) have 
identified multiple promising candidate genes for COPD, including FAM13A, HTR4, RIN3, HHIP, ADAM19, 
CHRNA3/5, AGER, and EEFSEC6–8. Estimated heritabilities in family aggregation studies are typically 30%9. 
Notwithstanding the importance of genetic architecture, AAT deficiency occurs in only 1 ~ 2% of COPD  patients5 
and the pathological role of most COPD candidate genes is  unknown10. Although COPD results from genetic 
and environmental factors,limited information is available regarding the genetic factors that actually contribute 
to COPD, and gene-environment interactions, except for AAT deficiency, have been difficult to  identify11.
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Nevertheless, COPD is known to be strongly influenced by cigarette smoking and multiple genetic vari-
ants, and recent studies have reported gene-environment interactions. For instance, Aschard et al.12 calculated 
the genetic risk scores for 26 genome-wide significant single nucleotide polymorphisms (SNPs), and reported 
significant interactions between genetic risk scores and smoking. In addition, both Hancock et al.13 and Park 
et al.14 hypothesized the existence of SNP-by-smoking interactions,the first performed a genome-wide interac-
tion study on pulmonary function, modelling the primary effects of single SNPs and their interactions, while 
the latter reported SOX9-by-smoking interactions. However, there is heteroscedasticity in pulmonary function 
between smokers and non-smokers. Furthermore, smoking has a nonlinear effect on pulmonary  function15, and 
the heterogeneity of this association has complicated SNP-by-smoking interaction analyses, thus limiting the 
number of identified interactions.
COPD is a progressive diseases that can be prevented but is  irreversible16, so the most effective way to pre-
vent COPD is primary prevention. Primary prevention involves two concepts: (1) to keep healthy individuals 
consistently healthy (health promotion), and (2) to prevent the onset or exacerbation of the diseases (disease 
prevention)17. Therefore, it is important to maintain healthy lung function, and we focus on the genetic and 
environmental factors in people with healthy lung function. In our previous  reports14, we analyzed whole indi-
viduals on  FEV1, and thus in this article, we aimed to identify genetic variants interacting with smoking, using 
spirometry measurements of  FEV1/FVC ratios from individuals with  FEV1/FVC ≥ 70 in the Korea Associated 
Resource (KARE), as this measurement determines the presence of airflow limitation and obstructive lung 
diseases such as COPD. We assessed significant SNPs on our genome-wide interaction study (GWIS) using 
Gene-Environment of Interaction and phenotype (GENIE) and Atherosclerosis Risk of a Rural Area in Korean 
General population (ARIRANG) data. We focused on potential SNP-by-smoking interactions considering only 
the SNPs that reached overall genome-wide significance levels.
Materials and methods
The KARE cohort was used for the discovery analysis in GWIS; GENIE and ARIRANG cohorts were included 
in validation analysis. Only participants with  FEV1/FVC ratio ≥ 70 were included.
Discovery analysis using KARE. The KARE project was initiated in 2007 for a large-scale GWAS, and 
participants constituting the independent Ansan and Ansung cohorts were included in the Korean Genome Epi-
demiology Study (KoGES)18. KoGES involved longitudinal prospective studies on 5018 participants in Ansung 
and 5020 participants aged 40–60 years in the Ansan area. KARE genotype data were obtained using the Affy-
metrix Genome-Wide Human SNP array 5.018, and quality control analyses were performed,8172 participants 
underwent spirometry analysis, and their smoking history was recorded (Fig. 1). Smoking history was obtained 
from questionnaires, and pack-years of smoking was considered for analyzing SNP-by-smoking interactions. 
Among the 8172 participants, 7473 participants showed  FEV1/FVC ratio ≥ 70; 4768 were non-smokers, 1140 
were former smokers, and 1565 were current smokers.
Validation analyses using GENIE and ARIRANG data. The GENIE cohort comprised 7999 partici-
pants agreeing to provide blood samples and to participate in genetic studies that had visited Seoul National 
University Gangnam Center in 2014.19 Participants underwent genotype analysis using the Affymetrix Axiom 
KORV1.1–96  Array20 and genotype quality control (QC) was performed. The 4413 participants with  FEV1/FVC 
ratio ≥ 70, age > 40 years, available spirometric data, and smoking history were included in the association analy-
sis. Based on questionnaires, 2520 individuals were non-smokers, 1380 were former smokers, and 513 were 
current smokers. From this dataset, the 2520 non-smokers and 513 current smokers were included in the GWIS 
validation study.
ARIRANG is an ongoing study on cardiovascular and metabolic risk factors, and participants aged 40–70 years 
are part of the KoGES study in rural Wonju and  Pyengchang21. The ARIRANG genotype data were obtained 
using the Affymetrix Genome-Wide Human SNP array 6.0, and genotype QC was performed. Spirometry data 
and smoking history were available for 513 participants with  FEV1/FVC ratio ≥ 70. Based on questionnaires, 369 
individuals were non-smokers, 65 were former smokers, and 79 were current smokers. All participants were 
included in the GWIS.
Quality control. For the discovery GWIS with KARE data, as well as for the validation analyses using 
GENIE and ARIRANG, the QC of SNPs and subjects was conducted using  PLINK22 and  oneTOOL23. We 
excluded SNPs with P values on the Hardy–Weinberg equilibrium (HWE) analysis < 10–5, minor allele frequen-
cies (MAFs) < 0.05, and genotype call rates < 95%. Furthermore, we excluded subjects with missing genotype call 
rates > 5% or sex-based inconsistencies. After QC, 311,556 SNPs and 7473 participants with  FEV1/FVC ratio ≥ 70 
were included for whole-genome imputation.
Genotype imputation. For GWIS with KARE data, whole-genome imputation was performed using SHA-
PEIT2 and IMPUTE2 for pre-phasing data and genotype imputations. The 1000 Genomes Phase 3 was used as 
the reference panel. To maintain imputation quality, the estimated imputation accuracy for imputed SNPs was 
evaluated using the INFO metric, and any imputed SNPs with INFO < 0.5 were eliminated. The standard QC 
procedure was also applied for imputed SNPs, and 3,351,033 SNPs from 7473 participants were used for the 
GWIS discovery study (Fig. 1).
For the validation analyses, genotypes comprising the most significant SNPs were not originally genotyped, 
and target imputation was conducted. Target imputation for regions containing significantly associated SNPs 
was performed using IMPUTE2 with a buffer size of 5 million bp for each target SNP.
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GWIS with KARE data. The GWIS discovery study of the  FEV1/FVC ratios with KARE data was con-
ducted for healthy individuals. We found that the most of our samples do not have any COPD, and the number 
of COPD patients is only 699. Genetic association analysis needs large sample  sizes24, and thus we decided 
to focus on healthy individuals with  FEV1/FVC ratio ≥ 70. To handle heteroscedasticity in pulmonary func-
tion between non-smokers and smokers, the weighted least squares regression was used with inverse variance 
weights according to smoking status (non-smoker or smoker). To assess the appropriateness of the weighted 
least analysis, we compared its Akaike Information Criterion with the linear regression coefficient, and found 
that the weighted least squares regression had better fit. Age, sex, BMI, age × sex, and pack-years of smoking were 
included as covariates. Principal component (PC) scores were estimated from the genetic relationship matrix, 
and 10 PC scores corresponding to the 10 largest eigenvalues were included as covariates to adjust the popula-
tion substructure. For the GWIS between each SNP and pack-years of smoking, we fitted the following weighted 
least squares regression. Considering yj the  FEV1/FVC values for smoking status j , and j =0 and 1, indicating 
non-smokers and smokers, respectively,
Here, for w1 and w2 , we estimated the residual variances from the linear regressions with only non-smokers and 
smokers, respectively, and the inverse of residual variances was used.
To identify SNPs interacting with pack-years of smoking on  FEV1/FVC values, we considered 
H0 : β6 = β7 = 0 , and the hypothesis was tested by the likelihood ratio (LR) test with two degrees of freedom 
(DF) for healthy individuals. To adjust the multiple testing issue, the P values for testing H0 : β6 = β7 = 0 was 
set to the genome-wide significant level of 5 × 10–8.
Validation studies. The genome-wide significant SNPs resulting from the GWIS discovery study were rep-
licated using the GENIE and ARIRANG datasets. For the ARIRANG dataset, similar to that performed for 
the GWIS discovery analysis, healthy individuals were included and the weighted least squares regression was 
fitted. However, for GENIE, the former smokers were excluded because they consisted of participants who had 













Figure 1.  Flow diagram for KARE cohort Fig. 1 explains how the individuals and SNPs were included and 
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regular health check-ups and consults for health improvement, including smoking cessation, regular exercise, 
etc.19 Even a short interference of 3 min is said to significantly increase the rate of smoking cessation among 
 smokers25, and this could bias the data. For the weighted least squares regression of the GENIE data, the weight 
was estimated using non-smokers and smokers.
A P value < 0.05 was set as the significance level in all analyses.
Topologically associating domains, PrediXcan, and expression quantitative trait loci analy‑
ses. Topologically Associating Domains (TADs) are genomic regions that exhibit high levels of chromatin 
interactions within a region or domain, but with little or no interaction with external  regions26. These domains 
are consistent across cell types and highly conserved across species, indicating that the TADs properties are 
strongly conserved in  mammals27. TADs were considered to identify boundaries where causal variants can 
greatly influence tissue-independent  function28. We used the web-based 3D Genome  Browser29 to identify TADs 
of significant SNPs from the GWIS and to confirm interactive protein-coding genes within TADs. We selected 
human tissues per the hg19 assembly and explored available high-throughput chromosome conformation cap-
ture (Hi-C) data from lung tissue obtained from donor 1 (Accessing number: SRX2179252 from GEO database).
PrediXcan, a gene-based approach for identifying genes associated with the phenotype of  interest30, imputes 
unobserved gene expression levels from genotypes and analyzes associations between imputed gene expression 
and phenotype. The imputation model for gene expression was developed for 48 different human tissues with 
Genotype-Tissue Expression (GTEx) V7 data. PrediXcan was used to impute gene expression of lung tissue and 
its association with the  FEV1/FVC ratio.
We analyzed expression quantitative trait loci (eQTL) to investigate genetic variants associated with gene 
expression levels. For the eQTL analysis, we used the GTEx portal providing reference resources of genetic vari-
ation and gene regulation in diverse human  tissues31.
SNP‑exposure independence. SNP-by-environment interactions can be significant in the absence of 
true SNP-by-environment interactions in cases of SNP-environment  dependencies32. Thus, correlations between 
most genome-wide significant SNPs from the GWIS discovery study and smoking were assessed. As smoking 
variables, we considered smoking status and pack-years, which were considered independent responses. SNPs 
were considered covariates for both scenarios. Smoking status was either non-smoker or smoker, and logistic 
regression analysis was conducted. For pack-years, linear regressions were performed.
Research ethics approval. This study complies with the scholarly and ethical conduct in research involv-
ing human participants. All study participants provided informed consent, and the study design was approved 
by the Institutional Review Board (IRB) at Seoul National University (IRB No. E1605/E002-003). All methods 
were performed in accordance with the relevant guidelines and regulations.
Results
GWIS of the  FEV1/FVC ratio among the healthy individuals from the KARE cohort. The GWIS 
of the  FEV1/FVC ratio was conducted for the 7473 healthy individuals and 3,351,033 SNPs that passed the 
QC (Fig. 1). The clinical characteristics of the healthy individuals in the KARE cohort are shown in Table 1. 
The quantile–quantile plot in Fig. 2A shows that GWIS statistics retained the nominal significance level (vari-
ance inflation factor = 1.002). The Manhattan plot in Fig. 2B shows that 11 SNPs at 6p21 reached genome-wide 
significance levels. As shown in Supplementary Fig. 1, these 11 SNPs were distributed in two separate linkage 
disequilibrium (LD) block. The regional plot in Fig. 3 shows that the most significant SNPs were found near 
TNXB, with many other proximal genes. The most statistically significant result was obtained for rs10947231, 
an intronic SNP located in TNXB, with PLR = 2.23 × 10–12 and corresponding PSNP = 1.42 × 10–10 and PINT = 0.84 
(Table 2). Here, PLR indicates the likelihood ratio test for H0 : βSNP = βSNP∗pack−years = 0 vs H1 : notH0.
The second genome-wide significant region was found near the NOTCH4 intron. In the linkage disequilib-
rium (LD) block, the rs8192575 SNP showed a genome-wide significant overall effect. The PLR was 1.18 × 10–8 
(Table 2). The coefficients for the SNP and interaction effects were 0.821 and − 0.02, respectively (PSNP = 1.77 × 10–9 
and PINT = 0.0165). These results indicated that if the genotype of rs8192575 is GG, the  FEV1/FVC ratio tends 
to increase to approximately 0.821 × 2; however, for smokers, the  FEV1/FVC ratios decrease to approximately 
− 0.02 × 2 per pack-year. Figure 4 indicates a significant difference in the  FEV1/FVC ratios between non-smokers 
and smokers. Figure 5 presents box-plots in accordance with the smoking status, age, and genotypes of rs8192575. 
In healthy individuals, the  FEV1/FVC ratios are consistently larger for non-smokers with genotypes GG and GC 
than for non-smokers with CC genotypes; however, for smokers, there are no significant differences in  FEV1/
FVC by allele G in rs8192575. Estimated  FEV1/FVC ratios in accordance with the pack-years is shown in Fig. 6. 
In Fig. 6, the decreasing rate of  FEV1/FVC is greater for individuals with genotypes GG and GC than genotypes 
CC. This indicates that the effect of allele G of rs8192575 is modified by pack-years of smoking.
Other nine significant SNPs were belonging in the same LD blocks with rs10947231 and rs8192575 (Sup-
plementary Fig. 1), and the results are summarized in Supplementary Table 1.
Validation analyses. The associations between rs10947231 and rs8192575 and the  FEV1/FVC ratio were 
further assessed using the healthy individuals in GENIE and ARIRANG cohorts. Clinical characteristics of 
healthy individuals these datasets are presented in Table 1. Table 2 shows that rs10947231 overall effects were 
replicated in the GENIE and ARIRANG data at P < 0.1 (PLR = 0.0698 for GENIE; PLR = 0.0714 for ARIRANG). 
However the main SNP effects were not significant for GENIE data. Interestingly, for ARIRANG data, rs10947231 
showed significant effects on both the SNP and interaction with PSNP = 0.0415 and PINT = 0.0583.
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According to Table 2, the overall effect of rs8192575 was significant for GENIE and ARIRANG data (PLR for 
GENIE = 0.0173 and PLR for ARIRANG = 0.0457). For the GENIE data, both the main SNP and interaction effects 
were replicated at 0.05 significance levels (PSNP = 0.0113 and PINT = 0.0454), and their regression coefficients were 
0.533 and -0.031, respectively. For the ARIRANG data, the interaction effect was replicated with -0.067 regression 
coefficients and 0.0131 P value. However, the main SNP effect was not significant (PSNP = 0.1471). The results 
for the other nine significant SNPs are presented in Supplementary Table 2, and are similar to those found for 
rs10947231 and rs8192575.
TAD, PrediXcan, and eQTL analyses. We considered chromatin TADs containing rs10947231 and 
rs8192575. TADs were defined using Hi-C to identify chromatin regions with physical contact. Most SNPs asso-
ciated with human disease or other phenotypes may develop associations through interactions with regulatory 
elements of a coding gene within the SNP-bearing  TAD33. Chromatin TAD analysis of lung tissue revealed that 
TNXB, NOTCH4, AGER, and C4B were in the same region (Supplementary Fig. 2). The most active interaction 
was observed in NOTCH4, followed by AGER, TNXB, and C4B, showing no significant differences.
PrediXcan analysis predicted susceptibility on the expression of chromosome 6 genes in lung tissue that 
regulate the  FEV1/FVC ratio. The results, summarized in Table 3, evidenced AGER (P value = 8.59 × 10–6) as the 
gene most associated with the  FEV1/FVC ratio. These results were significant at the conservative Bonferroni-
adjusted 0.05 significance level (P value < 1.1 × 10–4).
Table 1.  Descriptive statistics of healthy individuals Means of variables and their standard errors are 
calculated for continuous variables.
KARE GENIE ARIRANG
Participants 7473 4413 513
Age (years) 52.0 ± 8.9 49.7 ± 6.8 59.0 ± 7.4
Gender
Male 3310 (44.3%) 2507 (56.8%) 208 (40.5%)
Female 4163 (55.7%) 1906 (43.2%) 305 (59.5%)
Body mass index (kg/m2) 24.7 ± 3.1 23.3 ± 2.8 25.3 ± 3.2
Height (cm) 159.8 ± 8.7 165.6 ± 7.9 157.5 ± 8.5
Smoking status
Non-smokers 4768 (63.8%) 2520 (57.1%) 369 (71.9%)
Former smokers 1140 (15.3%) 1380 (31.3%) 65 (12.7%)
Current smokers 1565 (20.9%) 513 (11.6%) 79 (15.4%)
Pack-years of smoking 22.8 ± 17.2 16.2 ± 24.1 27.5 ± 15.3
FEV1 (liters) 2.9 ± 0.7 3.0 ± 0.6 2.4 ± 0.6
FVC (liters) 3.6 ± 0.9 3.7 ± 0.8 3.1 ± 0.8
FEV1/FVC ratio 81.4 ± 5.4 81.7 ± 5.5 79.2 ± 5.1
Figure 2.  Quantile–quantile plot and Manhattan plot from GWIS with healthy individuals in KARE data (A) 
is obtained from the comparison between observed P values quantiles relative and expected quantiles under 
the uniform distribution (null hypothesis). The variance inflation factor (VIF) was 1.002, suggesting our results 
are free of systematic P value inflation. (B) was plotted from the logarithms of the P values of 3,351,033 SNPs 
against its physical chromosomal position. The red line represents genome-wide significance level (5 × 10–8), and 
several SNPs located at 6p21 meet this significance level. The plot was generated by software R version 3.6.1 (R 
Foundation for Statistical Computing; Vienna, Austria).
6
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:13075  | https://doi.org/10.1038/s41598-020-70092-0
www.nature.com/scientificreports/
Figure 3.  Genomic region on chromosome 6 near rs10947231 and rs8192575 Fig. 3 suggests that the 
rs10947231 and rs8192575 located at gene dense region. The plot was generated by software R version 3.6.1 (R 
Foundation for Statistical Computing; Vienna, Austria).
Table 2.  Results for rs10947231 and rs8192575 from discovery GWIS For  FEV1/FVC, GWIS was 
performed on healthy individuals with 3,351,033 SNPs, and the genome-wide significant result are 
summarized. βSNP and βINT are the coefficients for the main SNP and interaction effects between SNP and 
pack-years of smoking, respectively. Overall effects indicate P values  (PLR) for testing the null hypotheses 
H0 : βSNP = βSNP−pack years = 0 by F test. BP physical position (Based on hg19), MAF minor allele frequencies, 




alleles MAF P value for HWE Missing rate INFO† βSNP(SE) PSNP βINT(SE) PINT Overall effects  (PLR)
rs10947231 Chromosome (BP) 6(32,054,346)
Discovery KARE A/C 0.165 0.767 0.015 0.983 0.835(0.13) 1.42 × 10
–10 0.001
(0.007) 0.8417 2.23 × 10
–12
Replication GENIE A/C 0.18 0.902 0 0.999 0.178(0.198) 0.3678
0.026
(0.014) 0.0684 0.0698
ARIRANG A/C 0.17 0.638 0.016 0.985 0.967(0,473) 0.04151
− 0.056
(0.03) 0.0583 0.0714
rs8192575 Chromosome (BP) 6(32,166,384)
Discovery KARE G/C 0.15 0.549 0.027 0.976 0.821(0.136) 1.77 × 10
–9 − 0.02
(0.008) 0.0165 1.18 × 10
–8
Replication GENIE G/C 0.163 0.425 0 1 0.533(0.21) 0.0113
− 0.031
(0.016) 0.0454 0.0173
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The eQTL of rs10947231 and rs8192575 were analyzed using GTEx (Supplementary Table 3). For rs10947231, 
no significant association between rs10947231 genotype and gene expression was found. For rs8192575, many 
eQTL genes, such as NOTCH4, C4B, and AGER were identified. Interestingly, AGER and C4B were differentially 
expressed in lung tissue, based on rs8192575. Thus, we further analyzed AGER and C4B expression using GTEx 
V7 data (Supplementary Fig. 3), and this revealed that AGER was upregulated in lung tissue, while C4B was 
expressed in adrenal glands and liver tissue. The numbers of transcripts per million kilobases for C4B and AGER 
in lung tissue were 5.53 and 1093.06, respectively.
In summary, it is unclear which gene, AGER or C4B, contributes to the significant effect of rs8192575 on the 
 FEV1/FVC ratio. However, AGER might be a more promising candidate gene due to its higher expression levels 
in lung tissue compared to that of C4B.
Figure 4.  Declines of  FEV1/FVC along age Changes in  FEV1/FVC along age according to smoking status and 
rs8192575 were plotted by generalized additive models (GAM). Figure 4 suggests that smoking has a significant 
effect on  FEV1/FVC ratios for healthy individuals. The plot was generated by software R version 3.6.1 (R 
Foundation for Statistical Computing; Vienna, Austria).
Figure 5.  The boxplot of the FEV1/FVC grouped by rs8192575, smoking status, and age from KARE data 
We visualized the effects of rs819275 on  FEV1/FVC according to smoking status and age. The plot represents 
the effects of rs8192575 for healthy individuals, and the allele G of rs8192575 has positive effects if healthy 
individuals have not smoked. The red diamond symbols represent mean value, which is displayed as a number. 
The plot was generated by software R version 3.6.1 (R Foundation for Statistical Computing; Vienna, Austria).
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Independence between rs8192575 and smoking. Significant SNP-by-environment interactions are 
detected in the absence of true SNP-by-environment interactions if SNP and the environment are correlated. 
Thus, we investigated whether rs8192575 and smoking are independent, considering smoking status and pack-
years as the smoking variables (Table 4). Supplementary Fig. 4 shows a boxplot of pack-years based on rs8192575; 
this SNP was not significantly associated with pack-years of smoking. Therefore, the statistical significance of the 
rs8192575-by-smoking interaction may indicate biological interactions, especially among subjects with normal 
lung function, and this could be true causal effects.
Discussion
The present GWIS including healthy individuals from the KARE dataset found that rs10947231 and rs8192575, 
located on chromosome 6 (6p21), were significantly associated with the  FEV1/FVC ratio in healthy individuals. 
Furthermore, rs8192575 showed significant interaction effects with the smoking variable pack-years of smoking. 
These associations was further investigated using data from two other Korean cohorts (GENIE and ARIRANG). 
For rs10947231 and rs8192575, both cohorts showed significant overall effects (P < 0.1) and significant interac-
tion effects with pack-years. The most significant findings were found in the introns of TNXB (rs10947231) and 
NOTCH4 (rs8192575). Region 6p21 is gene-dense, including genes TNXB, PPT2, C4B, NOTCH4, and AGER, 
among others. We conducted TAD, PrediXcan, and eQTL analyses to confirm the strongly associated genes. We 
confirmed that rs8192575 was strongly associated with AGER in lung tissues, and AGER has been previously 
described as susceptible for lung function and COPD. The rs10947231 does not have any eQTL genes. Its MAF 
in Europeans were 0.058 and 0.002 with 1000 Genome and  gnomAD34, respectively, and its low MAF may induce 
non-significance of its eQTL analysis. Considering that rs10947231 is in the TADs block of AGER region, and 
DNA sequences within TAD interact more frequently with each other than those outside TAD, there are some 
possibilities of significant association between AGER and rs10947231.
AGER is a protein coding gene which encodes RAGE belonging to the immunoglobulin superfamily and cell-
surface  receptor35. The RAGE has been extensively studied, and it significantly contributes to lung development 
and to maintain adult lung homeostasis, as evidenced by its upregulation on the membrane and cytoplasm of both 
Figure 6.  Estimated FEV1/FVC according to pack-years of smoking and rs8192575 The estimated  FEV1/FVC 
ratio is generated by gene-by-smoking analysis using healthy individuals of KARE. Figure 6 implies that minor 
alleles G has negative impact in proportion to each increment of pack-years of smoking. The plot was generated 
by software R version 3.6.1 (R Foundation for Statistical Computing; Vienna, Austria).
Table 3.  Result of PrediXcan for  FEV1/FVC ratio on KARE using lung tissue prediction model The results for 
PrediXcan for the top 10 genes on chromosome 6 are summarized.
Gene PrediXcan Beta PrediXcan P value
AGER − 2.797 8.59 × 10–6
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Type 1 alveolar cells and  macrophages36. A recent study suggested that RAGE upregulation during lung develop-
ment inhibits alveolar morphogenesis and induces significant changes in morphometric parameters, including 
a reduction in airspace and an increase in alveolar duct  size37. Lee et al.38 reported that the blockade of RAGE is 
significantly associated with decreased pulmonary inflammation and inhibits the activation of damage-associated 
molecular patterns in mice exposed to tobacco smoke. Indeed, RAGE expression increased after exposure to 
tobacco smoke and in COPD  patients39 suggesting that RAGE suppression protects against COPD. The eQTL 
analysis revealed that the minor allele G of rs8192575 was associated with lower AGER expression in lung tissue; 
thus, AGER may be downregulated in individuals with a larger number of G alleles. Figures 4 and 5 show that 
participants with G alleles also tended to have a greater  FEV1/FVC ratio, suggesting that AGER is associated with 
rs8192575 (This result is consistent with the previous report that RAGE suppression protect against COPD). The 
circulating soluble RAGE (sRAGE), acting as decoy receptors, has been robustly demonstrated that low sRAGE 
levels are associated with advanced COPD and lung function decline, which may be counterintuitive with our 
results. One possible explanation is that the effect of genetic variants on sRAGE protein levels is affected by 
environmental exposure, which indicates gene × smoking interaction effects. Another possibility is that genetic 
variants that promote the association between sRAGE and lung disease susceptibility have different  mechanism40.
Nonetheless, this study has some limitations. First, the 6p21 gene-dense region and C4B might have affected 
the eQTL and PrediXcan results. Gene C4B is a product of complement C4 activated in the early stage of the 
mannose-binding lectin  pathway41, and some studies have reported that C4B is associated with tissue damage in 
pulmonary tuberculosis  patients42,43. However, C4B was not upregulated in lung tissues (Supplementary Fig. 3), 
and its role in pulmonary function is still lesser known than that of AGER. Thus, we concluded AGER is a more 
promising candidate gene for COPD. Second, the most significant SNP, rs10947231, showed P = 1.42 × 10–10 
for its main effects in the KARE dataset, but only the ARIRANG data replicated this significance. Because 
rs10947231 was not directly associated with AGER, allelic and locus heterogeneities could be possible reasons 
for the failure to replicate such significant effects in the GENIE dataset. Third, the rs2070600 located in AGER, 
previously reported to be associated with the  FEV1/FVC ratio in the European population and associated with 
COPD, emphysema, and sRAGE levels, was not examined in our study. This SNP was excluded in our discovery 
GWIS during genotype QC and it did not show statistically significant interaction effects (PLR = 1.673 × 10–15, 
PSNP = 1.87 × 10–13, PINT = 0.984), potentially due to differences in the study population. These differences may 
be attributable to differences in genetic ancestry and LD structure among populations. Fourth, the overall and 
main SNP effects of rs8192575 were significant throughout the genome (significance level = 5 × 10–8). However, 
SNP-by-smoking interactions were significant at a relatively high significance level, i.e., at 0.05. Analyses of gene-
by-environment interactions often present numerous false-negative results, concurrent with the present findings. 
Hence, a larger sample is necessary to obtain genome-wide significant results to analyze gene-by-environment 
interactions. Fifth, our functional analyses (eQTL, TAD, and PrediXcan) have some limitations. For eQTL and 
TAD, the relevance of their results depends on tissue type. COPD and  FEV1/FVC are particularly related to lung 
tissue and it was chosen. However it is still possible that the other tissue can be a better  choice44. Furthermore, 
the prediction model of PrediXcan was built by European but it was applied to Korean. In such case, the predic-
tion accuracy can become  worse45,46.
In conclusion, we identified genome-wide significant effects at the 6p21 region using the  FEV1/FVC of healthy 
individuals, and rs8192575 showed significant interaction effects with smoking. Indeed, 6p21 is a gene-dense 
region, as characterized by previous GWAS.7,8,47 However, significant results were obtained with healthy indi-
viduals, and evidence regarding its significant interaction effects with smoking were found in Korean cohort 
data. The MAF of rs8192575 for the European population was 0.083 with 1000G European samples. Therefore, 
the lack of significant results so far might be due to low allele frequencies. However, for Koreans, the MAF was 
relatively high (0.15 to 0.18), and rs8192575 seems to have a significant effect on the Korean population. We 
expect that these results potentially provide insights into COPD pathogenesis and on the effect of smoking on 
lung function, concurrent with previous GWAS and biological reports.
Table 4.  Independence test between rs8192575 and smoking variables We tested gene-smoking dependency. 
The association between rs8192575 and pack-years of smoking are analyzed by linear regression, and the 
association between rs8192575 and smoking status are analyzed by logistic regression. For KARE and 
ARIRANG data the smoking status indicates non- and ever-smokers. For GENIE data smoking status indicates 
non- and current smokers. P value greater than 0.05 suggests that there was no dependency between rs8192575 
and smoking variables.
DATA P value from healthy individuals
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Data avilability
Genotype and clinical data for KARE and ARIRANG can be downloaded from https ://korea bioba nk.re.kr fol-
lowed by an approval process from Korean NIH. For more detail information for approval process, please contact 
to biobank@korea.kr. All type data for GENIE cohort is available on request at https ://en-healt hcare .snuh.org/
HPEAC Estud y. In addition, all the data analyzed in this article was utilized in previously published articles 
(KARE: Cho et al. 18, ARIRANG: Huh et al.21, GENIE: Lee et al.19.
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